Group 1 - The Forbes China Year-End Gala held on February 4, 2026, in Shanghai gathered outstanding entrepreneurs and industry leaders from technology, healthcare, semiconductors, and investment sectors to discuss future trends in artificial intelligence, hard technology, biomedicine, and business civilization [2] - Forbes China has been releasing various rankings since entering the Chinese market in 2003, including the Best CEO in China and the Top 50 Innovative Companies in China, which serve as important references for observing changes in China's business society [2] - The event featured a forum with keynote speeches and roundtable discussions covering topics such as healthcare, technology, talent, and sustainable development, aimed at exploring industry development trajectories and prospects [4] Group 2 - The keynote speech by Han Xu, CEO of WeRide, emphasized the strategic significance of autonomous driving as the first large-scale application of physical AI, predicting that within five years, everyone could stop driving, leading to the era of household service robots [6] - Chen Zhisheng, CEO of WuXi Biologics, forecasted that tumors could become controllable chronic diseases within five years, similar to diabetes, and discussed the transformative application of digital technology in drug production [12] - Xu Siqing, founder of Alpha Community, highlighted the dual nature of technological advancement, particularly in AI, which presents both opportunities and challenges to existing human life orders [16] Group 3 - Zhang Hua, founder and chairman of Shibang Group, warned that the era where labor is no longer a necessity is approaching, urging companies to design new job structures for collaboration between humans and intelligent agents [18] - Zhu Jia, partner at Guanghe Venture Capital, pointed out that the core bottleneck limiting AI development is not semiconductor chips but power supply, which is driving nuclear fusion technology towards commercialization [20] - The roundtable discussions included insights on the semiconductor industry's supply-demand mismatch, with Wu Shengwu, chairman of Rongxin Semiconductor, noting a structural contradiction where high-end demand faces capacity shortages while non-specialty processes are oversupplied [27] Group 4 - Liu Yuqing, assistant president of Huafeng Technology Group, emphasized the critical role of advanced packaging in enhancing computing power in the post-Moore's Law era, advocating for a focus on deepening capabilities in the domestic equipment sector [29] - Fang Ling, co-founder of CGL, observed a shift in talent competition within the semiconductor industry from purely technical talent to composite talent with commercial awareness, predicting that AI will exacerbate workplace differentiation [31] - The event also recognized companies like Huafeng Technology and Microchip Technology for their innovative contributions to the industry, awarding them the "2025 Forbes China Innovation Power 50" [58]

Group 1 - The Hang Seng Index fell by 1.13%, down 304 points, closing at 26,580 points, while the Hang Seng Tech Index decreased by 0.47% [1] - Three new stocks were listed: Dazhu CNC (03200) rose by 18%, Muyuan Foods (02714) increased by 4.72%, and Zhuozheng Medical (02677) surged by 34% [1] - Zhongxin Hang (03931) saw a 3.83% increase, with a 630% year-on-year growth in commercial battery deliveries and plans for full circulation of H-shares [1] - Long Resources (01712) experienced a 30% intraday surge, with expected net profit growth of up to 3.8 times year-on-year [1] - Changfei Optical Fiber (06869) rose over 10%, with institutions optimistic about fiber optic manufacturers benefiting from price increases [1] - Nuo Cheng Jianhua (09969) increased by over 11%, achieving profitability for the first time due to the volume of Obutinin and growth in BD revenue [1] - Nine Dragons Paper (02689) rose over 5%, benefiting from improved self-sufficiency in wood pulp and favorable industry supply-demand dynamics [1] - Jiaxin International Resources (03858) increased by over 5%, supported by supply contraction driving up tungsten prices [1] Group 2 - Fuhong Hanlin (02696) rose over 5% after licensing rights to Hanshuo in Japan to Eizai for a total transaction amount of approximately $388 million [2] Group 3 - Tongda Group (00698) increased by over 6%, expecting to turn a profit with a maximum earnings forecast of 125 million HKD for the previous year [3] - NIO-SW (09866) rose over 5%, marking its first quarterly profit with an expected adjusted operating profit of up to 1.2 billion CNY for the last quarter [3] - Cryptocurrency ETFs and related stocks continued to decline, with Bitcoin dropping below $65,000 amid ongoing sell-offs in the crypto market [3]

据悉，斯鲁利单抗是复宏汉霖自主研发的一款创新抗PD-1单克隆抗体。在中国，斯鲁利单抗已获批用 于多项适应症，包括鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)、非鳞状非小细胞肺 癌(nsqNSCLC)以及食管鳞状细胞癌(ESCC)。在欧盟，斯鲁利单抗已获批用于ES-SCLC适应症，并成为 全球首个用于ES-SCLC一线治疗的抗PD-1单抗。 复宏汉霖(02696)早盘涨超5%，截至发稿，涨4.64%，报63.15港元，成交额3262.22万港元。 消息面上，复宏汉霖公告，公司将抗PD-1单抗H药汉斯状(斯鲁利单抗)日本权益授权给卫材。卫材将向 复宏汉霖支付7,500万美元的首付款，并在此基础上，支付最高不超过8,001万美元的监管里程碑付款， 以及最高不超过2.333亿美元的销售里程碑付款。此外，复宏汉霖还将基于产品销售额获得双位数比例 的销售提成。 ...

据悉，斯鲁利单抗是复宏汉霖自主研发的一款创新抗PD-1单克隆抗体。在中国，斯鲁利单抗已获批用 于多项适应症，包括鳞状非小细胞肺癌(sqNSCLC)、广泛期小细胞肺癌(ES-SCLC)、非鳞状非小细胞肺 癌(nsqNSCLC)以及食管鳞状细胞癌(ESCC)。在欧盟，斯鲁利单抗已获批用于ES-SCLC适应症，并成为 全球首个用于ES-SCLC一线治疗的抗PD-1单抗。 消息面上，复宏汉霖公告，公司将抗PD-1单抗H药汉斯状(斯鲁利单抗)日本权益授权给卫材。卫材将向 复宏汉霖支付7,500万美元的首付款，并在此基础上，支付最高不超过8,001万美元的监管里程碑付款， 以及最高不超过2.333亿美元的销售里程碑付款。此外，复宏汉霖还将基于产品销售额获得双位数比例 的销售提成。 智通财经APP获悉，复宏汉霖(02696)早盘涨超5%，截至发稿，涨4.64%，报63.15港元，成交额3262.22 万港元。 ...

Major Events - Genting New Year (01952) subsidiary signed an agreement with Macao to commercialize MT1013 in Greater China and other Asian markets [1] - Junshi Biosciences (02696) entered into a licensing agreement with Eisai for Hansizhuang® to treat tumor indications [1] - Meituan-W (03690) plans to acquire all issued shares of Dingdong Fresh Holding Limited [1] - China Power (02380) subsidiary Xinyuan Zhichu signed a procurement contract for BESS with Tori [1] - Aimee Vaccine (06660) successfully passed the registration site inspection for its globally self-researched serum-free rabies vaccine [1] Operating Performance - NIO-SW (09866) issued a profit warning, expecting adjusted operating profit of 700 million to 1.2 billion yuan in Q4 2025, turning from loss to profit year-on-year [1] - Saint Bella (02508) issued a profit warning, expecting adjusted net profit of no less than 120 million yuan for 2025, a year-on-year increase of no less than 183% [1] - Geek+ (02590) achieved orders of 4.137 billion yuan in 2025, a year-on-year growth of approximately 31.7% [1] - China Overseas Development (00688) achieved contract property sales of approximately 14.478 billion yuan in January, a year-on-year increase of 20.4% [1] - Swire Properties (01972) reported a rental rate of 96% for Swire Plaza in Q4, with rents down by 13% [1] - Greentown China (03900) reported total contract sales of approximately 9.7 billion yuan in January, a year-on-year decrease of 14.16% [1]

在日本，除用于广泛期小细胞肺癌和非微卫星高度不稳定型转移性结直肠癌的治疗外，复宏汉霖还计划 在日本开展汉斯状用于胃癌围手术期治疗的临床研究，并将承担该产品在日本的上市许可持有人(MAH) 责任。 本报讯(记者金婉霞)2月5日，上海复宏汉霖生物技术股份有限公司(以下简称"复宏汉霖")与卫材株式会 社(以下简称"卫材")共同宣布，双方已就抗PD-1单抗H药汉斯状(斯鲁利单抗)在日本达成一项独家商业 化及共同独家开发与生产许可协议。 记者从复宏汉霖获悉，目前，该公司正在日本开展一项针对广泛期小细胞肺癌的二期桥接临床试验，并 计划基于该试验的结果等数据材料，于卫材的2026财年期间递交上市申请。此外，复宏汉霖也正在推进 汉斯状针对非微卫星高度不稳定型转移性结直肠癌的国际多中心三期临床试验，其他新适应症的开发也 在规划之中。 汉斯状是复宏汉霖自主研发的一款创新抗PD-1单克隆抗体。根据协议，卫材将获得汉斯状在日本的独 家商业化权益。卫材将向复宏汉霖支付7500万美元的首付款，并在此基础上支付最高不超过8001万美元 的监管里程碑付款，以及最高不超过2.333亿美元的销售里程碑付款。此外，复宏汉霖还将基于产品销 售额获得 ...

2月5日，复宏汉霖与卫材共同宣布，双方已就抗PD-1单抗斯鲁利单抗，在日本达成一项独家商业化及 共同独家开发与生产许可协议。 根据协议，卫材将获得斯鲁利单抗在日本的独家商业化权益。除用于广泛期小细胞肺癌和非微卫星高度 不稳定型转移性结直肠癌的治疗外，复宏汉霖还计划在日本开展斯鲁利单抗用于胃癌围手术期治疗的临 床研究，并将承担该产品在日本的上市许可持有人（MAH）责任。 在日本， 广泛期小细胞肺癌与非微卫星高度不稳定型转移性结直肠癌患者群体规模分别约有1.3万与2.8 万人，这两类疾病均存在着高度未满足的临床需求。 Copyright © 2025 PHARMCUBE. All Rights Reserved. 免责申明：本微信文章中的信息仅供一般参考之 用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。 2月5日，复宏汉霖与卫材共同宣布，双方已就抗PD-1单抗斯鲁利单抗，在日本达成一项独家商业化及 共同独家开发与生产许可协议。 卫材将向复宏汉霖支付7,500万美元的首付款（约合116亿日元*），并在此基础上，支付最高不超过 8,001万美元的监管里程碑付款（约合124亿日元 ...

Core Viewpoint - Japan's Eisai has entered into a licensing agreement with Shanghai Henlius Biotech for the lung cancer drug Hansizhuang, involving an upfront payment of $75 million and potential milestone payments totaling up to $313.34 million [1] Group 1 - Eisai will pay an upfront fee of $75 million to Henlius for the licensing rights to Hansizhuang [1] - The agreement includes additional milestone payments that could reach up to $313.34 million, contingent on the achievement of specific targets [1] - This partnership highlights the growing collaboration between Japanese and Chinese biopharmaceutical companies in the oncology sector [1]

2025年，我们实现了从单品授权出海向体系化价值出海的质变，我们新增4款产品登陆海外市场，我们自主研发的H药 汉斯状®、HLX11、HLX14在欧美主 流市场接连获批，多产品矩阵在欧美主流市场协同推进，标志着我们的多产品矩阵已具备在全球生物药主流市场协同作战的能力。在广阔的新兴市场，H药 汉斯状®成为印度唯一获批小细胞肺癌的PD-1抑制剂，上市12天即惠及150余位患者。这一系列成功不仅是产品的胜利，也是复宏汉霖质量体系、临床数据 和注册策略获得全球监管机构系统性认可的证明，更印证了中国药企在全球主流医药市场实现系统性突破的实力。 背景介绍： 当2025年的日历翻至末页，生物医药产业正站在一个特殊的历史节点——这既是"十四五"的收官沉淀之年，更是"十五五"宏伟蓝图的启航之时。这一年，技 术狂飙与商业理性的碰撞、全球化布局与本土化深耕的平衡、"创新驱动"向"价值驱动"的范式转型，共同勾勒出2025年的行业主线。2026年，产业如何跨越 技术周期与资本周期的双重考验，在"健康中国"战略与全球创新格局双轨并行中，探寻可持续增长路径？思享启发思想，"生物医药大健康2026思享汇：双 轨并行・破局生长"重磅上线，与核心 ...

本文源自：金融界AI电报 复宏汉霖(02696.HK)公告，公司与日本制药公司EisaiCo.,Ltd.订立许可协议，公司将授予Eisai独家许 可，供其于区域及领域内商业化许可产品汉斯状®（斯鲁利单抗注射液）。Eisai将向本公司支付首付款 7500万美元，监管里程碑款项合计至多8001万美元，基于许可产品于区域内的各项监管里程碑达成情况 支付；商业销售里程碑款项合计至多2.3333亿美元，基于许可产品于区域内的年度净销售额水平达成情 况支付以及以许可产品于区域内的年度净销售额的两位数百分比计的特许权使用费。 ...